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Abstract
The possibility of detecting genetic mutations rapidly in physiological media through liquid biopsy has attracted the attention
within the materials science community. The physical properties of nanoparticles combined with robust transduction methods
ensure an improved sensitivity and specificity of a given assay and its implementation into point-of-care devices for common use.
Covering the last twenty years, this review gives an overview of the state-of-the-art of the research on the use of gold nanoparticles
in the development of colorimetric biosensors for the detection of single-nucleotide polymorphism as cancer biomarker. We discuss
the main mechanisms of the assays that either are assisted by DNA-based molecular machines or by enzymatic reactions, summa-
rize their performance and provide an outlook towards future developments.
Introduction
Cancer is a leading cause of death accounting for about
8.8 million deaths in 2015 [1]. The list of tumor-linked
substances, i.e., biomarkers for diagnosis and prognosis
purposes is continuously increasing. Cancer biomarkers are
present in tumor tissues or serum and encompass a wide variety
of molecules, including DNA, mRNA, enzymes, metabolites,
transcription factors, and cell surface receptors. The first report
on cell-free DNA in body fluids by Mandel and Metais in 1948
[2], opened the possibility to screen the presence of a disease
through a simple blood test, setting thus a milestone of “liquid
biopsy”. Liquid biopsy has the potential to accelerate the early
cancer diagnosis by the detection of biomolecules such as cell-
fee DNA directly in blood samples.
Currently, the development of liquid biopsies is directly linked
to the state-of-the-art of advanced techniques in the field of
genomics such as digital PCR, next generation sequencing
(NGS), fluorescence in situ hybridization (FISH) and
BEAMing. These facilitate the fast design of mutational profiles
of tumor DNA, helping the prioritization of anti-cancer therapy.
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Although these techniques are without parallel in the analysis of
genetic material and the detection of mutations, they require an
operation by specialized personnel in large infrastructures such
as hospitals or research centers. The democratization of liquid
biopsy and therefore the advancement of personal medicine
needs efficient point-of-care devices that are simple to use
(preferentially colorimetric), disposable and cost-efficient,
making them available to a wide range of users. It has been
shown that progress in the development of such devices
requires improved strategies for signal transduction, which
might rely on the use of emergent nanomaterials.
Over the last decade, a number of novel and optically active
nanomaterials involving semiconductor or metal nanocrystals
enabled the development of sensing devices with rather simple
transduction mechanisms [3]. For example, the aggregation-in-
duced color change of a solution containing plasmonic nanopar-
ticles (from red to blue) in the presence of molecules offers an
excellent tool for colorimetric sensing without the need of using
advanced techniques. Similarly, selective fluorescence
quenching of organic dyes or semiconducting nanoparticles by
plasmonic nanoparticles offers an unprecedented sensitivity in
native physiological media. Coupling these nanomaterial-based
systems with enzymatic reactions can further increase the sensi-
tivity and selectivity of a given sensor, leading to a scenario in
which a tiny structural alteration of a biomolecule can be
detected within seconds even at sub-picomolar concentration.
Here, we review recent advancements in the development of
sensors based on metallic nanoparticles for the detection of
mutations in circulating tumor DNA molecules. By introducing
the importance of DNA molecules as biomarkers in the field of
liquid biopsy and by discussing current technologies in clinics,
we review the performance of recent sensors for single-point
mutation in which gold nanoparticles act as signal transducers.
We classify the discussed sensors according to whether the




Tissue biopsy is the state-of-the-art protocol in clinics for the
evaluation of tumor progression. This procedure, however,
constitutes a significant barrier for monitoring oncogenic muta-
tions since it can introduce clinical risks for the patient [4],
heterogeneity of tumor cells [5], and difficulties in the sampling
of tumor cells that in turn can lead to inadequate amounts of
tissue for genetic testing. Thus, the possibility of extracting
valuable biochemical information on tumor progression directly
from physiological media became a straightforward solution to
the issues of conventional biopsy. Table 1 summarizes the main
benefits of liquid biopsy concerning cancer diagnosis, predic-
tion and prognosis emphasizing that it is a promising tool in
monitoring tumor-specific changes during the entire course of
the disease. It can be used for the early-stage detection of
cancer, the identification of indicators for disease recurrence
and progression and the evaluation of a given treatment in
nearly real-time. In the context of the present review, the early-
stage diagnosis of cancer by novel sensing devices is priori-
tized in the subsequent discussion.
Table 1: Benefits of liquid biopsy in diagnosis, prediction and prog-
nosis of cancer.
stage information/benefits ref.
diagnosis early detection [6-11]
monitoring of minimal residual disease [12-15]
prediction assessment of molecular heterogeneity
of overall disease
[16,17]
monitoring of tumor dynamics [18-20]
identification of genetic determinants
for targeted therapy
[21,22]
evaluation of early treatment response [23,24]
assessment of evolution of resistance
in real time
[25,26]
prognosis identification of high risk of recurrence [27]
correlation with changes in tumor
burden
[28,29]
Circulating tumor DNA and single-nucleotide
polymorphism
The list of biomarkers that are present in blood and that exhibit
potential for cancer diagnosis experiences continuously grows.
These biomarkers include circulating tumor cells (CTCs) [30],
circulating membranous structures [31], circulating cell-free
nucleic acids (cfDNA) [4], microRNA, RNA [32] and proteins
[33] (Figure 1). For the discussion here, the detection of circu-
lating cell-free DNA is relevant. While all types of cells (tumor
and nonmalignant) release cfDNA into the extracellular system
[34], the circulating tumor DNA (ctDNA) is released uniquely
by tumor cells. Several release mechanisms have been identi-
fied. 1) Secretion after cell death through apoptosis and
necrosis, 2) secretion from tumor cells in the form of free or
encapsulated DNA fragments, and 3) secretion from phagocy-
tized tumor cells [35-38]. It has been observed that with the
increase of tumor load, the local fraction of ctDNA increases
compared to the overall amount of cfDNA in the sample [39].
However, this tendency is patient-dependent. The average
length of ctDNA fragments generated from cell apoptosis
ranges from 145 to 180 bp. Longer fragments of up to 10 kbp
are secreted by cell necrosis [40-44].
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Figure 1: Alterations in cell-free DNA. Cell-free DNA can be released from both cancerous and normal cells located in the tumor environment through
apoptosis, necrosis or secretion. Once in the bloodstream, cfDNA may exist either free or associated with extracellular entities such as exosomes.
cfDNA can carry multiple classes of tumor-derived genetic alterations including point mutations, copy-number fluctuations and structural rearrange-
ments. Reprinted with permission from [45], copyright 2017 Springer Nature.
Moreover, in solid malignancies, circulating tumor DNA differs
from cell-free DNA by somatic mutations [18,46,47]. In
leukemia, for example, the increased amount of cfDNA origi-
nates from cancer cells. Nonetheless, four main types of gene
alterations occurring in cfDNA are classified:
1. Single-point mutations or single-nucleotide polymor-
phism (SNP). A base substitution at one nucleotide that
may result in a change of the amino acid sequence of the
encoded protein or premature truncation of the protein
(Figure 2).
2. Copy-number alteration. Duplications, insertions or
deletions of one or a few nucleotides leading to the addi-
tion or subtraction of amino acids in the protein.
3. Exon or gene copy-number changes. Large duplica-
tions or deletions encompassing entire exons (protein-
encoding regions in a gene) and affecting the functional
domains of the protein.
4. Structural modifications. Translocations or inversions
within a gene that result in fusion genes and associated
fusion proteins.
Among these four gene alterations, the SNPs in ctDNA are
known as the major contributors to the genetic variations, repre-
senting more than 80% of all known polymorphisms at a fre-
quency of around 1 every 1000 bases [48]. To date, around
1.42 million single-base variations have been identified. These
small variations may occur in noncoding or coding regions of
the genes. SNPs in coding regions can be either synonymous
(without altering the encoded amino acid) or nonsynonymous
(altering the encoded amino acid), hence, possibly altering the
function of the corresponding protein (Figure 2) [49,50].
Figure 2: Single-nucleotide polymorphisms (SNPs) are genetic muta-
tions that alter single base in DNA, causing sequence modification in
amino acids and malfunction of a corresponding protein. Reprinted
with permission from [51], copyright 2014 Elsevier.
Approximately, 50% of all SNPs occur in noncoding regions,
25% are silent mutations with no effect on gene function and
phenotype, and the remaining 25% lead to mutations of the
gene function [52,53]. These SNPs can influence the promoter
activity (gene expression), the activity of messenger RNA
(mRNA), gene conformation (stability) and the translational
efficiency. Keeping in mind the importance of these modifica-
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tions, SNPs can be proposed as biomarkers in the clinical diag-
nosis of diseases, personalized medicine and drug treatment.
Genotyping is an essential process in determining which genetic
variants alter the encoded amino acid sequence and thus the
function of a given protein. Based on the molecular mechanism,
the majority of SNP genotyping assays fall in one of four
groups [54,55]. These include (1) allele-specific hybridization
(mutation-dependent hybridization of short nucleotides with
variable target DNA), (2) primer extension (DNA polymerase-
based incorporation of specific desoxyribonucleotides comple-
mentary to the DNA template, (3) allele-specific ligation
(ligase-based covalent linking of two oligonucleotides upon
hybridization on a DNA template), and (4) invasive cleavage
(nuclease-based cleavage of the 3D structure formed when two
overlapping oligonucleotides hybridize perfectly to a target
DNA). The genotyping method should meet several require-
ments, namely, facile development from sequence information,
cost-efficiency, robustness of the reaction, scalability, high-
throughput discrimination and the possibility for automatiza-
tion with minimal hands-on operation. We will demonstrate in
the following sections that the advancement of laboratory-based
sensors for SNP discrimination benefits from the current state-
of-the-art in genotyping techniques in SNP determination, espe-
cially in the context of conceptual novelty.
Tumor-specific aberrations containing SNP
Because the fraction of circulating DNA that is derived from
the tumor can range between 0.01% and 93% [41], analytical
techniques of high sensitivity are currently implemented to
obtain reliable information on tumor-associated genetic modifi-
cations and to follow tumor dynamics [4,16,46,56]. These tech-
niques are mainly modifications of the well-known polymerase
chain reaction (PCR), establishing thus the state-of-the-art in
clinics in the discrimination of SNP. The most relevant types of
cancer including colorectal, breast, ovarian, pancreatic and lung
cancer comprise several common tumor-specific aberrations of
single-point mutations, which are frequently selected as targets
in the development of novel biosensors based on nanoparticles.
Further below, we describe the working principles of biosen-
sors that were designed for the detection of the primary tumor-
specific aberrations listed in Table 2.
Colloidal gold as a signal transducer in SNP
detection
With the increased diversity of available optically active nano-
materials, optical assays have attracted wide interest. Particular-
ly attractive is the colorimetric detection of analytes in a liquid
phase, which represents a direct way to evaluate the presence of
an analyte by the naked eye. This facilitates its implementation
as a transduction system in point-of-care devices. Therefore,
Table 2: Tumor-associated genetic modifications in circulating cell-free
DNA.a
tumor type tumor-specific aberration
colorectal cancer [18] APC, KRAS, PIK3CA, TP53
breast cancer [19] PIK3CA, TP53, BRCA1
ovarian cancer [56] TP53, PTEN, EGFR, BRAF, KRAS




aKRAS = Kirsten rat sarcoma; APC = adenomatosis polyposis soli;
PIK3CA = phosphatidylnositol-4,5-bisphosphate 3-kinase catalytic
subunit alpha; TP53 = tumor protein p53, BRCA1 = breast cancer
gene 1, PTEN = phosphatase and tensin homolog, EGFR = epidermal
growth factor receptor, BRAF = B-Raf proto-oncogene, serine/threo-
nine kinase.
noble metal nanoparticles (metallic gold) are widely applied in
the development of biological sensing devices. Gold is an inert
metal that exhibits exceptional chemical stability in physiologi-
cal media and the readiness for surface functionalization with
desired biomolecules through stable Au–S bonds. The key prop-
erties of gold nanoparticles are their optical properties, which
yield an exceptional light absorbance in the visible spectral
range. This is explained by the fact that in the metallic core, the
conductive electrons experience coherent oscillations in the
presence of incoming electromagnetic radiation, thereby giving
rise to the so-called localized surface plasmon resonance
(LSPR). The position and the bandwidth of the LSPR can be
modulated by the shape of the nanocrystals and can vary be-
tween 400 and 2000 nm. The high absorption cross section
(plasmonic nanoparticles absorb photons over a region about
ten times larger than their physical diameters) [59], and the lack
of photobleaching (unlike organic fluorescent dyes and semi-
conductor nanocrystals) are additional parameters making plas-
monic nanocrystals attractive materials for biosensing. Impor-
tantly, the position of the plasmon band and its bandwidth are
also strictly related to the local environment. The collation of a
nanoparticle at a nanometric distance from the surface of
another nanoparticle induces a redshift of the maximum of the
surface plasmon band because of plasmon coupling, causing a
color change of the solution. Thus, the control over aggregation
or redispersion processes is of paramount importance in the
design of devices for the naked-eye detection of molecular
events on the surface of nanoparticles.
The early experiments by Mirkin and co-workers [60,61] on the
aggregation of gold nanoparticles stabilized with radially distri-
buted single-stranded DNA (Au@DNA) through selective
hybridization of complementary DNA opened up new possibili-
ties in the development of colorimetric sensors capable of
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Figure 3: Gold nanoparticle-based colorimetric assays in the colloidal phase. a) Cross-linking hybridization assay: Through the specific hybridization
of DNA, the distance between the particles decreases leading to a color change. b) Noncross-linking hybridization assay: An increase in the ionic
strength causes an aggregation of nanoparticles (blue solution), which is prevented by the presence of the complementary target. c) Colorimetric
assay based on unmodified nanoparticles: Single-stranded DNA (ssDNA) stabilizes gold nanoparticles against salt-induced aggregation, while in the
presence of double-stranded DNA (dsDNA) particles undergo aggregation.
discriminating single-point mutations. This methodology
comprised the selective aggregation of two types of noncomple-
mentary DNA-stabilized gold nanoparticles of 13 nm in diame-
ter (Figure 3a). A target oligonucleotide (24–30 bases) that was
complementary to the single-stranded DNA (ssDNA) of both
types of nanoparticles induced an aggregation through hybridi-
zation. The main advantage of this method is the low risk of
false positives.
Maeda et al. have proposed the so-called noncross-linking
method for SNP detection, which is based on the nonselective
aggregation of one single type of DNA-coated gold nanoparti-
cles (Figure 3b) [62]. The target DNA (15 bases) containes a
single-point mutation at the 5′ terminus, which provides steric
stability to the nanoparticles, thus ensuring colloidal stability at
a higher salt concentrations. On the contrary, the perfect match
sequence (mutation-free 5′ terminus) formed a rigid double-
stranded DNA (dsDNA) on the particle surface, decreasing
steric and electrostatic repulsions, thereby causing gradual
aggregation. This method allows for a sensitivity of 500 nM in
the discrimination of single-base mutation.
Rothberg and Li proposed the use of citrate-stabilized gold
nanoparticles instead of DNA-coated nanoparticles, which are
prone to aggregate at a high salt concentration [63]. The
working principle of this system rests on the fact that ssDNA
exhibits a higher affinity to the surface of metallic gold as
dsDNA. This is because ssDNA molecules contain a large num-
ber of functional groups facilitating electrostatic interactions
with the gold surface (Figure 3c). Therefore, at a high salt con-
centration, adsorbed ssDNA stabilizes the nanoparticles against
aggregation. In contrast, the preferential hybridization of target
Beilstein J. Nanotechnol. 2020, 11, 263–284.
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30 nt/— hybridization assay 10 fmol [60]
AuNPs
(13 nm)
24 nt/— colloidal stability of NPS in the presence of ssDNA or dsDNA 100 fmol [63]
AuNPs
(13 nm)
24 nt/— hybridization assay 10 pmol [61]
AuNPs
(13 nm)
14 nt/— salt-induced aggregation of unmodified AuNPs 0.25 µM [65]
AuNPs
(18 nm)
20 nt/EGFR salt-induced aggregation of unmodified AuNPs 80 µM [66]
AuNPs
(13 nm)
41 nt/JAK2 salt-induced aggregation of unmodified AuNPs 0.2 µM [67]
AuNPs
(13 nm)
22 nt/— a logic gate using two distinct target DNA molecules as input to discriminate




34 nt/— the product of the catalytic strand displacement cascade disassembly AuNPs 0.1 µM [69]
AuNPs
(13 nm)
14 nt/— hybridization assay based on Au@LNA/DNA chimeras 0.1 µM [70]
AuNPs
(15 nm)





noncross-linking aggregation of Au@DNA within rpoB locus 30 µg/mL [71]
AuNPs
(14 nm)















24 nt/CFTR hybridization assay using a miniaturized optical monitoring system 10 nM [75]
AuNPs
(15 nm)
22 nt/— sequential hybridization to the target by allele-specific surface-immobilized






24 nt/— hairpin-based amplification assay combined with lateral flow test 10 pM [77]
AuNPs (13,
20, 40 nm)






27 nt/— MBs@DNA, Au@DNA and target hybridization followed by magnetic







27 nt/— sandwich assay between target, Au@DNA and a flatbed scanner; signal




84 nt/EGFR hairpin assembly produces short DNA catalyst, which induces aggregation of
unmodified AuNPs
7.7 fM [81]
AuNRs 24 nt/— combination of HCR and unmodified gold nanorods for signal transduction 1.47 nM [82]
AuNPs
(13 nm)










22 nt/— oriented aggregation of nanoparticles on Y-shaped DNA duplex 10 pM [85]
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30 nt/— MBs@DNA, Au@DNA, target hybridization followed by magnetic separation




265 nt/hepatitis C release and adsorption of free primers on the nanoparticle ensuring stability 50 copies [87]
AuNPs
(75 nm)
22 nt/— hybridization assay 3 nM [88]
AuNPs (5, 10,
12, 20 nm)
60 nt/KRAS target-stabilized nanoparticles interacting with matching or mismatching






20 nt/— DNA hybridization-mediated autocatalytic overgrowth of gold nanoparticles 60 nM [90]
AgNPs
(13 nm)
22 nt/— PNAs induce aggregation of citrate-stabilized AuNPs, which is prevented by






selective aggregation of PNA-stabilized AuNPs by target DNA and positively




30 nt/hepatitis A combination of “click chemical” ligation chain reactions on gold nanoparticles




















22 nt/miR-21 DNA I located on SiO2MPs captures miRNA, DNA II labeled with EDTA·2Na
























36, 48, 80 nt/— nanoparticle amplification assisted by nicking endonuclease (NEase) for the




24 nt/keratin 10 isothermal strand displacement polymerase reaction to produce




40 nt/— aggregation of Au@DNA in the presence of single-strand-specific nuclease 100 nM [103]
AuNPs
(13 nm)
22 nt/miR-122 miRNA–probe heteroduplex as substrate of double strand nuclease,




43 nt/EGFR coupling of invasive reactions with NEase-assisted nanoparticle amplification









23 nt/— coupling of polymerase and NEase through an isothermal exponential




30 nt/KRAS cyclic enzymatic cleavage based on Exo III in the presence of the target and





46 nt/BRCA1 Au@DNA complexed with magnetic beads using horseradish peroxidase





34 nt/— combination of padlock probe for rolling-circle amplification and
NEase-assisted nanoparticle amplification
1 pM [110]
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isothermal target and probe amplification for the hybridization of target








single‐base primer extension in combination with noncrosslinking assay 1 μM [112]
AuNPs
(13 nm)














57 nt/PKD1 fluorescence-enhancement from nanoparticle-hybridized DNA complexes by





22 nt/miR-141 target-triggered CHA and fluorescence enhancement of DNA–silver
nanoclusters to detect miRNA
0.3 nM [117]
AuNPs (5 nm) 24 nt/— distance-dependent modulation of electrochemiluminescence from CdS:Mn




19 nt/miR-21 p19-QDs with multiplex antenna capture miRNA-21/antimiRNA-21-Cy3
duplex to form a Förster resonance energy transfer (FRET) detection system
between QDs and Cy3
0.6 fM [119]
MBs (1 μm) 21 nt/miR-27a dual toehold-mediated circular strand displacement amplification-based DNA
circuit as fluorescent strategy for the detection of miRNA-27a
0.8 pM [120]
fluorescence/enzyme-aided
AuNPs (5 nm) 25 nt/— enhancement of the electrochemiluminescence of a CdS film by a
combination of an isothermal circular amplification reaction of polymerase,
NEase and Au@DNA
5 aM [121]
QDs (15 nm) 21
nt/miR-196a2T





52 nt/H7N9 virus carbon nanodot‐based fluorescent sensing strategy for H7N9 utilizing




22 nt/miR-141 pentaethylenehexamine- and histidine-functionalized graphene QD for a
microRNA fluorescence biosensing nanoplatform coupled with molecular
beacon double-cycle amplification
0.43 aM [124]
QDs (5 nm) —/miR-148,
miR-21
QD-assisted FRET signal generation 42 fM [125]
optical microscopy
AuNPs (5 nm) 22 nt/LET7 differential interference contrast microscopy with a microarray platform























DNA with complementary strands left the nanoparticles uncov-
ered, facilitating aggregation. The authors were able to detect
single-base mismatches at the level of 43 nM using gold nano-
particles of 13 nm. This method, however, had a rather low
selectivity and could only differentiate DNA strands containing
three or more mismatched bases.
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These examples are characterized by their simplicity requiring
no expensive equipment or reagents. The detection of SNPs was
achieved by mixing a DNA target with a probe followed by the
direct naked-eye readout. The need for further improvements
motivated the researchers to increases the complexity of the
assays. Today, the methods for SNP detection can be classified
as enzymatic and nonenzymatic. In enzyme-free strategies, the
signal amplification is achieved by a cascade of hybridization
reactions prior to the optical signal transduction. One of the
mechanisms that are discussed in the following section benefits
from free energy driving cascades of toehold-mediated strand-
displacement reactions. Other heavily exploited mechanisms are
based on the formation of DNA circuits and include hybridi-
zation chain reaction (HCR), catalytic hairpin assembly (CHA)
and entropy-driven catalysis [64]. These mechanisms have
shown a great potential for developing biosensors of high sensi-
tivity and high selectivity since the target DNA itself is used as
a catalyst to cyclically amplify the process of DNA self-
assembly. The strategies based on enzymatic tools, on the other
hand, are characterized by an extraordinary potential for signal
amplification. The main advantages of using enzymes involve:
a) the capability of modifying oligonucleotides (e.g., poly-
merases, nucleases, helicases, ligases), b) an extraordinary cata-
lytic activity and c) biocompatibility. Table 3 summarizes the
examples for the detection of DNA targets with single-point
mutations using gold nanoparticles as signal transducers. We
classified the assays by the used enzymatic reactions for signal
amplification.
Enzyme-free SNP discrimination using gold
nanoparticles
Although the first works on the selective aggregation of
Au@DNA by complementary ssDNA offered a conceptual
novelty in the field of biosensing, the simple aggregation of
nanoparticles via complementary target DNA suffered from low
detection sensitivity and selectivity. To overcome these limita-
tions, new amplification methods were proposed using diverse
molecular mechanisms. Mirkin and co-workers have imple-
mented a bio-bar-code method to detect single-point mutations
in target DNA associated with the anthrax factor [79]. The
assay comprised magnetic beads coated with a sequence of
oligonucleotides and Au@DNA modified with two types of
oligonucleotides (1:100 ratio), one that was complementary to
the target sequence and the other complementary to a bar-code
sequence. The magnetic beads and the Au@DNA formed a
sandwich structure linked by the target sequence, which was
magnetically separated from the wild-type DNA. This process
was followed by the release of bar-code sequences, which
were then captured on a chip-based scanometric system
and amplified via the autocatalytic reduction of silver(I) by
hydroquinone. The authors demonstrated a sensitivity of
500 zM, which translates to about ten copies in 30 μL of the
sample.
To improve the sensitivity of the colorimetric sensors, several
groups have proposed to use modified nucleic acids. The most
common modified nucleic acids are peptide nucleic acids
(PNAs) and locked nucleic acids (LNAs), which are obtained
by intercalating natural and artificial nucleobases or by modi-
fying internucleoside linkages. Lee and co-workers have pro-
posed the colorimetric detection of a point mutation in codon
559 of c-Kit using targets of different lengths (12-, 21- or
42-mer) [92]. PNA-coated AuNPs (18 nm) were complementa-
ry to the wild-type target sequence that hybridized with the
PNA probes on the AuNPs. This hybridization made the parti-
cles negatively charged because of the phosphate backbone in
the target DNA sequences preventing their aggregation.
Uncharged particles underwent aggregation. The detection limit
was 100 fmol/μL for a target with 21 bases. Chakrabarti and
Klibanov built an assay based on the difference in the thermal
stability of PNA–DNA and DNA–DNA duplexes [131]. The
authors observed that the PNA-modified AuNPs aggregated due
to the neutralization of the charges of the PNAs. Upon the addi-
tion of complementary DNA, the colloidal stability was recov-
ered because of the hybridization of the negatively-charged
DNA with the neutral PNA-modified AuNPs. The group of
Graham has reported the functionalization of AuNPs (13 nm)
with LNAs, revealing a remarkable binding affinity and selec-
tivity towards DNA targets with 22 bases [70]. The use of
LNA/DNA chimeras enhanced the stability of duplexes formed
with AuNP conjugates, which could discriminate between
mismatching DNA and complementary target DNA at a detec-
tion limit of 100 nM.
The use of unmodified gold nanoparticles as signal transduc-
tors is another strategy for the selective detection of SNPs.
Zhou and co-workers have proposed the use of binary DNA
probes that were split in the middle and complementary to the
target DNA [67]. Upon the addition of target DNA to the solu-
tion of binary DNA probes and citrate-protected AuNPs of
13 nm in diameter, the hybridization between the target DNA
and the binary DNA probes enhanced the salt-induced aggrega-
tion. However, the presence of DNA molecules with single-
base mismatches prevented the aggregation of AuNPs and the
solution remained stable. This approach yielded a detection
limit of 5 nM. Lee and co-workers have reported the detection
of mutations in exon 19 and exon 21 of the epidermal growth
factor receptor (EGFR) isolated from both the lung cancer cell
lines and the cancer tissues of patients with non-small-cell lung
cancer [66]. The citrate-stabilized gold nanoparticles under-
went selective aggregation upon the addition of mutated DNA
that hybridized with the complementary probe of 20 bases. Yet,
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Figure 4: Discrimination of SNPs by means of the kinetics of particle aggregation. a) The spurious catalyst decelerates the toehold-exchange reac-
tion and thus the formation of aggregates. (b) Time-dependent change of the color of the assay using spurious and correct targets. Reprinted with
permission from [83], copyright 2014 John Wiley and Sons.
the gold nanoparticles remained stable in the presence of wild-
type DNA complementary to the probe sequence. In the eight
specimens of non-small-cell lung cancer patients, the deletion
of the mutant form of exon 19 and the L858R point mutation in
exon 21 were detected at a concentration of 10 ng/μL.
Another strategy to improve the sensitivity of colorimetric bio-
sensors based on plasmonic nanoparticles is the use of a molec-
ular tool known as toehold-mediated strand displacement [132],
in which one strand of DNA (output) is exchanged spontane-
ously with another strand (input). In such a process, an original
ssDNA strand, which is complexed with a protector ssDNA, has
a region – the toehold – that is complementary to the third
strand of an ssDNA – the invading strand. The displacement
starts with the selective hybridization of the invading strand
with original strands, followed by a progressive branch migra-
tion of the invading domain to finally displace the protector
ssDNA. The process is energetically favored since the reverse
reaction is slower by several orders of magnitude. When the
protector strand possesses a toehold region, it can turn into an
invading strand itself, giving rise to a strand-displacement
cascade. Duan et al. have proposed the use of a toehold-medi-
ated strand-displacement cascade, in which the product of the
strand displacement (length of 34 bases) was consumed by the
disassembly of AuNPs [69]. The assay allowed for an SNP dis-
crimination at a detection limit of 1 nM in a complex physiolog-
ical medium such as fetal bovine serum.
Liang and co-workers [83] built on the previous results and de-
veloped a strategy to discriminate single-base mutations
through the assembly of AuNPs driven by a DNA-fueled mo-
lecular machine (Figure 4). In their design, the initial mixture
contained two different types of nanoparticles: first, AuNPs
functionalized with multi-stranded DNA molecules (S), and
second, Au@DNA acting as the fuel. The key in the design of S
were two open-terminal domains, named α and γ. A reaction
was initialized by a catalyst (X) binding to the γ domain of S.
Thus, releasing a by-product, an intermediate species was pro-
duced, which had a single-stranded region complementary to
the DNA sequence of the fuel. In the next step, the fuel dis-
placed the catalyst X, resulting in the cross-linking aggregation
of the two DNA–AuNP complexes. The catalyst was released
back into the solution. The authors observed that the aggrega-
tion of nanoparticles was slower by a factor of 10 when the se-
quence of the catalyst contained single-base mismatches
(spurious catalyst). This colorimetric bioassay could detect
single-base changes associated with the breast cancer gene
BRCA1. The detection limit was 0.26 nM, corresponding to
31.2 fmol of a target.
Recently, advances in the development of DNA circuits based
on hybridization and strand-exchange reactions have attracted
much attention. Two examples of DNA circuits are commonly
exploited, HCR [133] and CHA [134], both introduced by the
Pierce group. These are based on the storage of potential energy
in two hairpin species. In HCR, a single-stranded DNA initia-
tor interacts with the first hairpin, exposing a new single-
stranded region, which in turn opens the second hairpin species.
Then, the chain reaction proceeds. Namely, single-stranded
regions that are identical to the original single-stranded DNA
Beilstein J. Nanotechnol. 2020, 11, 263–284.
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Figure 5: Working principle of the colorimetric assay for the detection of EGFR mutants in long DNA sequences. The presence of a target releases
the catalyst oligonucleotide initiating CHA, which in turn progressively aggregate gold nanoparticles. Reprinted with permission from [81], copyright
2018 John Wiley and Sons.
initiator get exposed and finally open other hairpins. As a result,
double helices are formed until all hairpins are consumed. On
the other hand, CHA relies on the exponential amplification of a
target sequence. In the presence of a target, the so-called hairpin
detection probe (HDP) is unfolded to form a duplex and expose
its concealed domain. The corresponding hairpin assistant probe
(HAP) replaces the target to form specific HDP/HAP com-
plexes. The target is released based on a thermodynamically
driven entropy gain process. The released target then triggers
the next cycle to produce numerous HDP/HAP complexes
[135].
In their work, Sang and co-workers [72] have proposed a
method called target-catalyzed hairpin assembly amplification.
Aggregation of nanoparticles at an elevated salt concentration
was prevented by three kinetically frozen hairpin structures,
which exhibited an affinity toward metallic gold. The addition
of a DNA target activated a cascade of assembly steps to form
stiff branched junctions, thus consuming all three hairpin struc-
tures. The electrostatic repulsion between the junctions and the
negatively charged AuNPs made negligible their binding to the
gold surface, leading to the aggregation at high salt concentra-
tions. By this method, a detection limit of 0.1 pM for a single-
point mutation in sequences of 16 nucleotides was achieved.
Chanho Park et al. [81] have extended this strategy by using
catalyst DNA (c-DNA) to discriminate single-base mutations in
long (84 molecules) EGFR mutated DNA. The catalyst c-DNA
was complementary to the so-called c-c DNA, a longer DNA
sequence (Figure 5). The introduction of target DNA to a solu-
tion containing c-DNA and c-c DNA led to the formation of
duplexes between c-c DNA and target DNA molecules. As a
result, c-DNA was released again and initiated the assembly of
branched junctions with three metastable hairpin DNA mole-
cules. Two of these hairpins were attached to the surface of
AuNPs, such that the formation of the branched junctions
altered the colloidal stability of the nanoparticles, leading to a
gradual aggregation. The detection limit of this method was
7.7 fM.
With the aim of improving the sensitivity of the plasmon-based
colorimetric sensor, Ying and co-workers [82] have used gold
nanorods as a signal transducers. Due to their intense longitu-
dinal surface plasmon band, gold nanorods exhibit a higher
sensitivity to changes of the colloidal stability as compared to
spherical nanoparticles. Thus, by using gold nanorods one can
lower the detection limit. The authors used unmodified gold
nanorods for an HCR process as illustrated in Figure 6. The
presence of a target DNA induced the hybridization of a hairpin
DNA, producing a nicked double helix. Through electrostatic
repulsion, this double helix prevented the aggregation of the
gold nanorods at high salt concentrations. However, in the
absence of a target DNA, the gold nanorods easily aggregated
because of weak protection by hairpin DNA. Following this ap-
proach, the authors were able to detect target DNA in a range of
0–60 nM at a detection limit of 1.47 nM. The method is highly
selective in distinguishing matching and single-base
mismatching DNA.
Enzyme-aided SNP discrimination
Owing to their high selectivity and strong catalytic properties,
enzymes are molecular tools capable of improving sensitivity
and selectivity of colorimetric sensors by several orders of mag-
nitude. The most commonly exploited enzymes are nucleases,
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Figure 6: The combination of unmodified gold nanorods as signal transducers in an HCR amplification process for the colorimetric detection of single-
base mutations. Reprinted with permission from [82], copyright 2018 Elsevier.
polymerases and ligases. Another advantage of using enzymes
is their capability to sustain catalytic cycles, thus amplifying the
number of available oligonucleotide sequences, which after
reaching a concentration threshold induce the aggregation of
nanoparticles. Therefore, a relatively low concentration of en-
zymes is required (1 U/µL) to maintain cyclic reactions and
amplify the concentration of the DNA strands. However, the
time required to reach the concentration threshold of a given
strand is relatively long (hours), slowing down the operation of
an assay. An additional drawback is that enzymatic reactions
require a precisely controlled temperature range to ensure
proper functioning, affecting the robustness of an assay under
real-world conditions. Nonetheless, as shown over the last
decade, the integration of enzymes into nanoparticle-based
colorimetric assays is a conceptual innovation in the discrimina-
tion of DNA mutations in complex physiological media.
To implement enzymes into assays for single-nucleotide dis-
crimination using gold nanoparticles as signal transducers,
exonuclease-assisted signal amplification (EASA) is common-
ly used. By coupling cyclic enzymatic cleavage and signal
amplification by gold nanoparticles, Yang and co-workers were
able to reach a detection limit of 15 pM [108]. Their system
consisted of exonuclease III (Exo III), a linker strand and two
batches of spherical Au@DNA (Figure 7). The linker was
hybridized with a target DNA forming a duplex that could be
digested by Exo III, which in turn led to the release of the target
for other binding/cleavage events. The linker sequence was
complementary to Au@DNA. When digested by Exo III, the
linker could not couple with the Au@DNA particles, thus
preventing particle aggregation. However, in the absence of a
target, no linker DNA was digested, allowing for the progres-
sive hybridization to Au@DNA and therefore aggregation. The
activity of Exo III strictly depends on the type of 3′ terminus
affecting the selectivity of the assay. More precisely, a fully
complementary target led to recessed 3′ termini, while a
mismatch yielded protruding 3′ termini. Hence, the method
allowed for the discrimination of single and triple-base
mismatches.
Ye and co-workers explored the duplex-specific nuclease
(DSN) [104] for the detection of microRNA (Figure 8). The
system consisted of a probe complex, DSN and two sets of dif-
ferent ssDNA-modified gold nanoparticles. The probe complex
is formed by two strands with a loop in the middle and hybridi-
zation regions at the termini. Target miRNA invaded the probe
complex forming a substrate (probe B) that was hydrolyzed by
the enzyme, leading to the release of probe A and target
miRNA. This cyclic invasion/digestion process caused a
gradual increase of the concentration of probe A, triggering the
aggregation of nanoparticles. Without a miRNA target, the
probe complex remained undigested and the colloidal stability
of the nanoparticles was conserved. DSN is capable of discrimi-
nating single-nucleotide mismatches in short DNA–RNA
duplexes. The method reached a detection limit of 5 nM for
mismatched miRNA (G-miR-122).
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Figure 7: Working principle of EASA for the colorimetric detection of DNA mismatches. The consumption of a large amount of linker DNA strands by
a few initial target molecules leads to the preservation of the colloidal stability of gold nanoparticles. In the absence of a target, the intact linker DNA
hybridizes with Au@DNA leading to a gradual color change. Reprinted with permission from [108], copyright 2011 Elsevier.
Figure 8: Schematic illustration of the colorimetric method for the detection of specific miRNA based on the amplification of DSN-assisted nanoparti-
cles using AuNPs as the signal output. Reprinted with permission from [104], copyright 2015 Royal Society of Chemistry.
Another enzyme-assisted approach used in the discrimination of
single-base mutations involves the combination of nicking
endonuclease (NEase) and DNA polymerase giving rise to the
so-called isothermal exponential amplification reaction
(EXPAR). The EXPAR technique uses a DNA template,
deoxynucleotide triphosphates (dNTPs) and two enzymes to
achieve the exponential amplification of a target sequence.
DNA polymerase and NEase are used in the same reaction mix-
ture. Once connected to the template, the trigger DNA is ex-
tended along the template by the DNA polymerase. After the
extension, the dsDNA contains the NEase recognition sequence,
and the NEase cleaves the extended trigger DNA strand. The
displaced strand and another template molecule then hybridize,
initiating a new amplification cycle [136,137].
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Figure 9: Colorimetric method for the detection of specific miRNA based on the combination of enzyme-assisted exponential amplification and AuNP-
based colorimetric detection. The sensing probe attached to the gold nanoparticles can be easily disrupted by the enzymes, ensuring thus an im-
proved performance. Reprinted with permission from [107], copyright 2016 Elsevier.
The group of Ye has used EXPAR with a sensing probe immo-
bilized on the surface of gold nanoparticles (Figure 9) [107].
The key point here was the design of the sensing probe, which
had three domains: a polyadenine block with a phosphorothio-
ate modification in the backbone, two sequences complementa-
ry to the target miRNA and a recognition site of the NEase.
When the target miRNA connected to the sensing probe, the
EXPAR process commenced. The DNA polymerase extended
the double-stranded fragment with a recognition site for an
endonuclease that nicked the fragment enabling its release. This
new fragment by being equal to the target miRNA, initiated a
new EXPAR cycle, leading to the release of the sensing probe
from the nanoparticles and as a consequence, their aggregation.
This method yielded a detection limit of the specific miRNA of
roughly 46 fM. In addition, the authors tested the selectivity of
this assay using G-miR-221-3p. This test revealed a relatively
good specificity, demonstrating that single-nucleotide differ-
ences between similar miRNAs members could be identified.
To improve visual detection of single-point mutation on device
conditions, Liu and co-workers developed an approach that
combined isothermal strand-displacement polymerase reactions
(ISDPR) and lateral flow strip (LFS) [102]. The mixture for
ISDPR comprised biotin-modified hairpin, digoxin-modified
primer, polymerase, and deoxynucleotide mixture (Figure 10a).
A mutant DNA hybridized with the hairpin probe, leading to a
conformational change, and stem separation (step 1), followed
by polymerization reaction by the polymerase (step 2), forming
biotin- and digoxin-attached duplex DNA (step 3). The process
was further amplified through the next cycle (step 4). Overall,
by the cyclic process, a large number of biotin- and digoxin-at-
tached duplex DNA were produced using a little amount of the
initial mutant DNA. The duplex DNA was later detected visu-
ally on the LFS through dual immunoreactions, using two
batches of gold nanoparticles functionalized either with anti-
digoxin and anti-biotin antibodies to obtain color signal at test
and control zones, respectively. With this test, authors were
able to detect visually the presence of R156H-mutant gene at
the concentration down to 1 fM.
Another interesting approach of using gold nanoparticles for
SNP detection is based on the fact that gold nanoparticles are
capable of quenching fluorescence through Förster resonance
energy transfer. By involving an isothermal circular amplifica-
tion reaction of polymerase and NEase, the group of Chen [121]
used gold nanoparticles to either quench or enhance the electro-
chemiluminescence of CdS films through the modulation of the
distance between metallic and semiconductor components by a
DNA machine (Figure 11). Their system consisted of a CdS
film, a composite of AuNPs (5 nm) and hairpin DNA, a primer,
and polymerase and NEase. In the presence of AuNPs–hairpin
DNA, the luminescence of CdS was quenched (Figure 11A).
The luminescence was recovered after adding target DNA,
causing a conformational transition from hairpin to linear DNA.
This opening initiated polymerization of DNA (Figure 11C),
which in turn displaced previously hybridized target DNA
(Figure 11D). In such a design, one target DNA strand could
open many hairpin DNA strands, increasing the fluoresce
signal. An additional increase of the fluorescence signal was
achieved by the action of NEase that nicked an extended double
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Figure 10: The combination of isothermal strand-displacement polymerase reactions and lateral flow strip for visual detection of gene mutations.
a) Schematic illustration of isothermal strand-displacement polymerase reactions and the formation of digoxin- and biotin- attached duplex DNA com-
plexes b) The mechanism of detection on lateral flow strip and c) visualization of the presence of mutation. Reprinted with permission from [102],
copyright 2012 Elsevier.
helix strand, allowing for a subsequent polymerization process
and displacement of the DNA trigger. The authors estimated
that the presence of one polymerase molecule and one NEase
molecule was enough to complete 22 cycles over a period of
40 min. The use of a target DNA with single-point mutation led
to a decrease of the relative fluorescence by 87%.
DNA ligase is an enzyme capable of repairing nicks, i.e.,
missing phosphodiester bonds, in a DNA sequence. Assays
based on such enzyme rely on the ability to covalently join two
oligonucleotides when they hybridize next to each other on a
given template. In an inverted scenario, one can use the
so-called padlock probe, a linear oligonucleotide with two ter-
Beilstein J. Nanotechnol. 2020, 11, 263–284.
278
Figure 11: The use of gold nanoparticles as fluorescence quencher in the discrimination of SNP through cyclic enzyme-aided polymerization and
nicking of oligonucleotides. The presence of a mutation decreases the fluorescence of the CdS films by nearly 90%. Reprinted with permission from
[121], copyright 2011 Royal Society of Chemistry.
minal segments complementary to a short target sequence.
Upon hybridization to a target DNA, the two ends become
juxtaposed and can be joined by a DNA ligase if there is a
perfect match. Liu and co-workers [110] have proposed the use
of a padlock probe that contained a segment with the sequence
identical to a linker probe a′–b′ and target-complementary seg-
ments at both termini of the molecule (Figure 12a). The ends
were brought in contact to form a circular oligonucleotide upon
hybridization to the target DNA in the presence of a DNA
ligase, serving as a template for a rolling circle amplification
reaction. The produced prolonged DNA containing copies of
the complementary sequence of the padlock template under-
went selective scission in the presence of endonuclease. As a
result, if the target DNA was complementary to the padlock
probe, the nicked linker block would bind to the complementa-
ry DNA attached to gold nanoparticles without aggregation. If
there was a mismatch, however, the linker probe would remain
intact, facilitating the gradual aggregation of nanoparticles
through hybridization. The authors demonstrated a colorimetric
discrimination of single-point mutation, which decreases when
the mismatch position is shifted away from the ligation site
(Figure 12b).
In another study, Zhou and co-workers have proposed a colori-
metric detection of DNA by coupling an invasive reaction
(strand displacement) with NEase-assisted nanoparticle amplifi-
cation [105]. In the proposed method, the target sequence was
first hybridized to two probes (up- and down-stream) followed
by enzymatic cleavage using flap endonuclease, producing
many flaps from a target DNA (Figure 13a). Then, in another
enzymatic reaction, the flaps were ligated with a P-oligo se-
quence, allowing for a nicking of the complementary strand
(Linker) by NEase. The amplified linker strands bound to
Au@DNA gold nanoparticles preventing their aggregation. In
contrast, in the absence of the target, the consecutive enzymatic
reactions were inhibited, leading to the preservation of the
linker strands, and its subsequent hybridization with gold nano-
particles, causing aggregation. The specificity of the method
was demonstrated by the discrimination of mutated strands
(1%) in the presence of a large amount of wild-type DNA back-
grounds (Figure 13b,c).
Conclusion
The last two decades of extensive studies have proven that plas-
monic nanoparticles (especially gold) exhibit properties that
facilitate their implementation in molecular assays the for
detection of genetic mutations in biological samples. Recent
results also show that further complexification and coupling of
the nanoparticles with DNA-based molecular amplification
tools is a way to provide tests of binary readout and of rational
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Figure 12: Colorimetric DNA detection through rolling circle amplification (RCA) and NEase-assisted nanoparticle amplification (NEANA). a) Working
principle of the assay. b) Colorimetric detection of single-point mutation located in the proximity of ligation point. Reprinted with permission from [110],
copyright 2012 John Wiley and Sons.
sensitivity, with limits of detection reaching real-world require-
ments. It is, however, noteworthy that recent advancements, as
discussed above, have been made mostly in the context of the
(bio)molecular components of given assays. That is, while the
amplification methods, based on DNA molecular machines or
enzyme-assisted processes, were the subject of constant
improvements, the plasmonic component remains barely
explored. However, a vast number of plasmonic nanomaterials
with different shapes, sizes and compositions is commonly
available, offering a broad range of optical properties not only
in the visible but also in the near-infrared spectral range. Shape
anisotropy (rods) and regiospecific surface functionalization
(tip versus lateral parts) enable the fabrication of colloidal
systems with limited degrees of freedom. In such systems, the
possible orientations of particles relative to each other are
restricted, which imposes a colorimetric transition, i.e., a
blueshift or redshift of the localized surface plasmon resonance
[138]. It is reasonable to assume that development of biosen-
sors for liquid biopsy will benefit from growing research on
dynamic self-assembly of nanoparticles, in which interparticle
forces [139], mutual orientation and interparticle distances are
well controlled by chemical stimuli. Finally, we foresee that the
detection of genetic mutations by plasmonic nanoparticles will
be strongly enhanced by a complementary detection of disease-
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Figure 13: a) The working principle of DNA target detection through an invasive reaction coupled with NEase-assisted nanoparticle amplification.
b) Optical characterization of the assay solution spiked with different amounts of c.2573 T>G mutant EGFR gene in the presence of a background
wild-type EGFR sequence, showing a specificity down to 1%. c) The relation of increased absorbance with increasing the relative concentration of
mutated sequence in assay mixture. Reprinted with permission from [105], copyright 2015 Elsevier.
related proteins. Specifically, the recently proposed protein
corona sensor arrays in which the composition of protein corona
reflects the presence of a given cancer enabled new venues in
detecting diseases directly from a blood sample [140]. More-
over, the simultaneous detection of genetic mutations and
disease-specific proteins, as shown recently [141], brings great
promises to liquid biopsy.
With the aim of reaching real-world applications, the current
assays, which have demonstrated functionality under laborato-
ry conditions, require optimization to be incorporated into
point-of-care diagnostic tools. Lateral flow tests are especially
attractive since they exhibit numerous advantages including
minimal operator-dependent interpretation of the test (binary
output), small value, low cost, relatively short detection time
(minutes), and the possibility for integration with personalized
electronic devices [142-145]. Still, the integration of different
stages such as sample preparation, molecular amplification, and
transduction zones requires new design of lateral flow devices
to become fully operative. Recent works, as the one by Liu et
al. discussed above, suggests the feasibility of such an ap-
proach [102].
Several limitations need to be addressed as well. One of the
known issues in colloidal biosensing is the spontaneous forma-
tion of a protein corona on the surface of the particles in physio-
logical media [146], inhibiting the interaction of the biomark-
ers with the colloid, thereby altering the sensitivity and selec-
tivity of an assay. The inhibition of binding events by the
corona layer may lead to false negatives, while corona-medi-
ated unspecific binding leads to false positives. To minimize the
protein adsorption, one can tailor the chemical composition of
ligands by the use of zwitterionic compounds or the use of
antifouling polymers such as polyethylene glycol.
Finally, the availability of whole-genome sequencing as offered
by recently established private companies (e.g., Veritas
Genetics and Novogene) allows for the determination of
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hundreds of mutations from a single sample at relatively low
cost (200 US dollars). However, the time required to complete
such an analysis exceeds several weeks, making it unfeasible
for the fast monitoring of tumor dynamics. Therefore, point-of-
care diagnostic tools that offer rapid (hours) discrimination of
an individual mutation remain an aim to be pursued in the
further development of personalized medicine.
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